Skip to main
ULBI
ULBI logo

Ultralife (ULBI) Stock Forecast & Price Target

Ultralife (ULBI) Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 50%
Buy 0%
Hold 0%
Sell 50%
Strong Sell 0%

Bulls say

Ultralife Corp experienced a strong top-line sales growth of 23.4% year-over-year, driven by record medical sales and significant increases in both Government and Defense (G&D) and Commercial segments, at 28.8% and 20.2% respectively. The company reported an improved gross profit margin of 25.6%, up from 22.4% year-over-year, reflecting enhanced operational efficiency amid the easing of supply chain constraints. Additionally, the positive cash flow from operations has enabled the company to initiate debt repayment, reducing interest burdens and positioning it favorably for continued growth as it launches new products and integrates the recent acquisition of ElectroChem.

Bears say

Ultralife Corp reported third-quarter revenues of $35.7 million, a decrease from $39.5 million year-over-year and falling short of the $43 million estimate. The company's adjusted EBITDA of $1.9 million also significantly underperformed expectations, being lower than the forecasted $5.2 million due to weaker top-line results. Contributing to this negative outlook, Ultralife faced supply chain challenges and delays in fulfilling large customer orders across both its Communications Systems and Battery & Energy Products segments.

Ultralife (ULBI) has been analyzed by 2 analysts, with a consensus rating of Hold. 50% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 50% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ultralife and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ultralife (ULBI) Forecast

Analysts have given Ultralife (ULBI) a Hold based on their latest research and market trends.

According to 2 analysts, Ultralife (ULBI) has a Hold consensus rating as of Jul 4, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $8.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $8.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ultralife (ULBI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.